- Real-world data from 122 patients with uncontrolled type 2 diabetes (T2D) with HbA1c levels above 7.0% (key threshold for diabetics to manage their condition) showed mean reductions of 1.3% after median duration of five months of V-Go use.
Catalyst
Slingshot members are tracking this event:
Data Released for Valeritas’(VLRX) V-Go Wearable Insulin Delivery Device on Reductions in A1c and Daily Insulin Usage
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VLRX |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 15, 2019
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
V-go, Insulin Delivery
